Compare · NVO vs WVE
NVO vs WVE
Side-by-side comparison of Novo Nordisk A/S (NVO) and Wave Life Sciences Ltd. (WVE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and WVE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 208.3x WVE ($1.03B).
- WVE has been more active in the news (30 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 20 for WVE).
- Company
- Novo Nordisk A/S
- Wave Life Sciences Ltd.
- Price
- $48.65+3.65%
- $5.26+2.73%
- Market cap
- $215.46B
- $1.03B
- 1M return
- -
- -11.30%
- 1Y return
- -
- -47.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 9
- 30
- Recent ratings
- 25
- 20
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest WVE
- SEC Form EFFECT filed by Wave Life Sciences Ltd.
- Director Wagner Heidi L sold $42,070 worth of shares (7,000 units at $6.01) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $5.97 (SEC Form 4)
- Director Rawcliffe Adrian sold $67,183 worth of shares (12,700 units at $5.29) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Director Tan Aik Na sold $2,596 worth of shares (432 units at $6.01) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,968 units (SEC Form 4)
- Director Takanashi Ken sold $23,223 worth of shares (3,864 units at $6.01) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 20,079 units (SEC Form 4)
- SEC Form 144 filed by Wave Life Sciences Ltd.
- Amendment: SEC Form SCHEDULE 13D/A filed by Wave Life Sciences Ltd.
- Wave Life Sciences Announces Completion of Redomiciliation to Delaware
- SEC Form S-8 POS filed by Wave Life Sciences Ltd.
- SEC Form S-8 POS filed by Wave Life Sciences Ltd.